Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Improved detection of cortical MS lesions with phase-sensitive inversion recovery MRI.
Neuropathology of white matter disease in Leber's hereditary optic neuropathy.
Fourth Cooperative Meeting of Consortium of MS Centers and Americas Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
Receptos initiates clinical trials for S1P1 agonist program, aimed at multiple sclerosis
Decreased microglial activation in MS patients treated with glatiramer acetate.
Analysis of Onset Mechanisms of a Sphingosine 1-Phosphate Receptor Modulator Fingolomod-Induced Atrioventricular Conduction Block and QT-Interval Prolongation.
Pharmacogenetic study of long-term response to interferon-β treatment in multiple sclerosis.
Ofatumumab Dose-finding in RRMS Patients
Spasticity improvement in patients with relapsing-remitting multiple sclerosis switching from interferon-β to glatiramer acetate: the Escala Study.
The Antiaging Protein Klotho Enhances Oligodendrocyte Maturation and Myelination of the CNS.
Mitoxantrone for multiple sclerosis.
National Cancer Institute Search for Clinical Trials
Laquinimod Study in Systemic Lupus Erythematosus (SLE) Patients With Active Lupus Nephritis
The role of T cell apoptosis in nervous system autoimmunity.
Cortical demyelination and diffuse white matter injury in multiple sclerosis.
Effect of Rituximab in Patients With Leucine-Rich, Glioma-Inactivated 1 Antibody-Associated Encephalopathy.
A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.
Quality of life and depression in multiple sclerosis patients: longitudinal results of the BetaPlus study.
The synthetic cannabinoid R(+)WIN55,212-2 augments interferon-β expression via peroxisome proliferator-activated receptor-α
Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.
Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis.
FDA Accepts Filing of BETACONNECT™* for Relapsing-Remitting Multiple Sclerosis Patients Taking BETASERON® (interferon beta-1b)
Effects of prophylactic and therapeutic teriflunomide in transcranial magnetic stimulation-induced motor-evoked potentials in the Dark Agouti rat model of experimental autoimmune encephalomyelitis.
Tecfidera(®): an approach for repurposing.

Pages